31753-00-1 Usage
Description
[1,1'-Biphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-2-oxo-4-[(1E)-3-oxo-1-octenyl]-2H-cyclopenta[b]furan-5-yl ester is a complex organic compound characterized by its unique molecular structure. It is an ester derivative of [1,1'-biphenyl]-4-carboxylic acid, featuring a hexahydro-2-oxo-4-[(1E)-3-oxo-1-octenyl]-2H-cyclopenta[b]furan-5-yl moiety. [1,1'-Biphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-2-oxo-4-[(1E)-3-oxo-1-octenyl]-2H-cyclopenta[b]furan-5-yl ester is known for its specific stereochemistry, with the 3aR,4R,5R,6aS configuration, which plays a crucial role in its biological activities and applications.
Uses
Used in Pharmaceutical Industry:
[1,1'-Biphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-2-oxo-4-[(1E)-3-oxo-1-octenyl]-2H-cyclopenta[b]furan-5-yl ester is used as an intermediate in the synthesis of Prostaglandin E2 (P838610). Prostaglandin E2 is the most common and biologically potent of mammalian prostaglandins, playing a significant role in various physiological processes, including inflammation, pain, and fever. [1,1'-Biphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-2-oxo-4-[(1E)-3-oxo-1-octenyl]-2H-cyclopenta[b]furan-5-yl ester is utilized in the development of pharmaceuticals targeting these conditions, making it a valuable asset in the pharmaceutical industry.
Used in Research and Development:
[1,1'-Biphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-2-oxo-4-[(1E)-3-oxo-1-octenyl]-2H-cyclopenta[b]furan-5-yl ester is also used in research and development for the study of prostaglandin biology and its role in various diseases. Understanding the structure-activity relationships and the mechanisms of action of this compound can lead to the discovery of new therapeutic agents and a better understanding of prostaglandin-related pathways.
Check Digit Verification of cas no
The CAS Registry Mumber 31753-00-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,1,7,5 and 3 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 31753-00:
(7*3)+(6*1)+(5*7)+(4*5)+(3*3)+(2*0)+(1*0)=91
91 % 10 = 1
So 31753-00-1 is a valid CAS Registry Number.
InChI:InChI=1/C28H30O5/c1-2-3-5-10-22(29)15-16-23-24-17-27(30)32-26(24)18-25(23)33-28(31)21-13-11-20(12-14-21)19-8-6-4-7-9-19/h4,6-9,11-16,23-26H,2-3,5,10,17-18H2,1H3/b16-15+/t23-,24-,25-,26+/m1/s1
31753-00-1Relevant articles and documents
A unified strategy to prostaglandins: chemoenzymatic total synthesis of cloprostenol, bimatoprost, PGF2α, fluprostenol, and travoprost guided by biocatalytic retrosynthesis
Chen, Fener,Huang, Zedu,Jiang, Meifen,Li, Weijian,Tang, Pei,Ye, Baijun,Zhang, Guo-Tai,Zhu, Kejie
, p. 10362 - 10370 (2021/08/16)
Development of efficient and stereoselective synthesis of prostaglandins (PGs) is of utmost importance, owing to their valuable medicinal applications and unique chemical structures. We report here a unified synthesis of PGs cloprostenol, bimatoprost, PGF2α, fluprostenol, and travoprost from the readily available dichloro-containing bicyclic ketone6aguided by biocatalytic retrosynthesis, in 11-12 steps with 3.8-8.4% overall yields. An unprecedented Baeyer-Villiger monooxygenase (BVMO)-catalyzed stereoselective oxidation of6a(99% ee), and a ketoreductase (KRED)-catalyzed diastereoselective reduction of enones12(87?:?13 to 99?:?1 dr) were utilized in combination for the first time to set the critical stereochemical configurations under mild conditions. Another key transformation was the copper(ii)-catalyzed regioselectivep-phenylbenzoylation of the secondary alcohol of diol10(9.3?:?1 rr). This study not only provides an alternative route to the highly stereoselective synthesis of PGs, but also showcases the usefulness and great potential of biocatalysis in construction of complex molecules.
Promotion of wound-healing with 15-keto-prostaglandin compounds
-
, (2008/06/13)
A method for promoting healing of wound which comprises administering, to a subject in need of such treatment, a wound-healingly effective amount of a 15-ketoprostaglandin compound.
Treatment of pancreatic disease with 15-keto-prostaglandin compounds
-
, (2008/06/13)
A method of treatment of pancreatic disease which comprises administering, to a subject in need of such treatment, a 15-keto-prostaglandin compound in an amount effective in treatment of pancreatic disease.